Zydus Life Science

Market Cap (₹ Cr.)

₹95,280

52 Week High

1,324.30

Book Value

₹197

52 Week Low

628.10

PE Ratio

22.27

PB Ratio

4.37

PE for Sector

37.21

PB for Sector

3.95

ROE

17.34 %

ROCE

20.43 %

Dividend Yield

0.32 %

EPS

₹41.43

Industry

Pharmaceuticals

Sector

Pharmaceuticals - Indian - Bulk Drugs & Formln

Investment Returns

In Long Term

In Short Term

1 Year

0.00%

2 Years

0.00%

3 Years

0.00%

4 Years

0.00%

5 Years

0.00%

Growth Rate

Revenue Growth

13.82 %

Net Income Growth

91.39 %

Cash Flow Change

20.05 %

ROE

70.49 %

ROCE

58.54 %

EBITDA Margin (Avg.)

23.08 %

Financial Results

Quarterly Financials	Mar 2015	Jun 2015	Sept 2015	Dec 2015	Mar 2016	Jun 2016	Sept 2016	Dec 2016	Mar 2017	Jun 2017	Sept 2017	Dec 2017	Mar 2018	Jun 2018	Sept 2018	Dec 2018	Mar 2019	Jun 2019	Sept 2019	Dec 2019	Mar 2020	Jun 2020	Sept 2020	Dec 2020	Mar 2021	Jun 2021	Sept 2021	Dec 2021	Mar 2022	Jun 2022	Sept 2022	Dec 2022	Mar 2023	Jun 2023	Sept 2023	Dec 2023	Mar 2024	Jun 2024	Sept 2024
Revenue	1,469	1,933	1,998	1,788	1,488	967	812	810	1,225	1,095	1,806	1,617	1,501	1,611	2,054	1,725	1,714	1,371	1,977	1,761	2,225	1,816	2,118	1,944	1,992	2,153	2,078	1,856	2,031	2,033	2,371	2,149	2,831	3,038	2,694	2,478	3,694	4,267	2,947
Expenses	991	1,187	1,163	1,137	968	740	694	716	759	844	1,088	1,149	1,082	1,121	1,135	1,219	1,262	1,161	1,156	1,360	1,345	1,207	1,429	1,608	1,415	1,506	1,844	1,472	1,519	1,437	1,583	1,554	2,011	1,815	1,510	1,672	1,772	1,787	1,678
EBITDA	478	746	835	650	520	227	118	94	466	250	717	467	419	490	919	506	452	210	821	402	881	609	688	336	577	647	234	385	511	596	788	595	820	1,223	1,184	806	1,922	2,480	1,269
Operating Profit %	26 %	32 %	34 %	28 %	28 %	14 %	3 %	-0 %	-0 %	15 %	36 %	24 %	22 %	21 %	28 %	24 %	21 %	9 %	20 %	16 %	21 %	29 %	27 %	12 %	27 %	26 %	4 %	14 %	21 %	22 %	29 %	19 %	18 %	37 %	26 %	25 %	44 %	56 %	33 %
Depreciation	56	52	55	55	60	59	69	68	55	66	70	78	79	84	88	90	88	90	105	110	112	111	112	113	115	117	119	120	123	123	124	122	120	121	125	128	131	131	134
Interest	14	6	8	6	7	6	6	4	-4	12	24	3	25	38	41	-16	25	26	83	48	63	20	15	16	21	44	24	25	42	41	64	89	85	90	91	104	106	115	96
Profit Before Tax	409	688	773	589	453	162	43	23	415	172	623	387	315	368	791	432	338	94	633	243	706	478	561	207	442	486	91	240	347	432	600	385	615	1,013	968	574	1,685	2,234	1,039
Tax	62	123	139	106	87	32	0	1	27	36	130	82	71	63	136	75	70	16	85	47	19	84	100	64	56	85	73	25	78	101	145	86	130	236	172	119	408	532	249
Net Profit	347	565	635	484	354	130	38	22	471	91	450	306	243	310	667	363	262	79	554	214	619	398	473	140	465	400	14	197	247	332	451	256	491	781	805	450	1,405	1,701	790
EPS in ₹	16.95	27.59	6.20	4.73	3.46	1.27	0.37	0.21	4.60	0.89	4.39	2.99	2.36	3.03	6.51	3.55	2.56	0.77	5.40	2.09	6.05	3.89	4.62	1.37	4.54	3.91	0.14	1.92	2.41	3.24	4.45	2.53	4.85	7.71	7.96	4.45	13.89	16.90	7.85

Show % Change

Above figures are in Rs. Crores

Balance Sheet

Balance Sheet	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Total Assets	7,337	8,923	11,047	12,164	13,671	16,552	18,464	17,740	20,564	24,085
Fixed Assets	1,768	2,155	2,352	2,680	3,933	4,109	4,112	4,336	4,184	4,369
Current Assets	2,697	2,923	2,139	3,557	4,262	4,793	6,032	6,837	7,158	7,911
Capital Work in Progress	367	297	678	659	675	553	571	384	739	634
Investments	458	2,317	3,924	3,618	4,195	6,404	6,471	5,118	4,879	7,283
Other Assets	4,744	4,154	4,093	5,206	4,868	5,486	7,310	7,902	10,761	11,799
Total Liabilities	2,812	2,647	4,429	4,418	5,102	5,291	5,719	4,500	6,924	8,368
Current Liabilities	2,020	1,922	3,014	2,791	2,806	3,449	4,821	4,028	2,790	2,541
Non Current Liabilities	792	725	1,415	1,628	2,296	1,842	898	472	4,134	5,827
Total Equity	4,525	6,276	6,618	7,746	8,569	11,260	12,745	13,241	13,639	15,717
Reserve & Surplus	4,423	6,174	6,516	7,643	8,467	11,158	12,642	13,138	13,538	15,616
Share Capital	102	102	102	102	102	102	102	102	101	101

Show % Change

Above figures are in Rs. Crores

Cash Flow

Cash Flow	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Net Cash Flow	120	14	-247	167	-67	268	-231	149	-54	-132
Investing Activities	-577	-1,016	-2,480	28	-713	55	-2,714	586	-1,959	-1,831
Operating Activities	1,084	1,956	863	288	581	1,180	2,227	1,272	1,078	1,999
Financing Activities	-387	-923	1,366	-149	65	-967	255	-1,710	827	-301

Show % Change

Above figures are in Rs. Crores

Share Holding

% Holding	Mar 2021	Jun 2021	Sept 2021	Dec 2021	Mar 2022	Jun 2022	Sept 2022	Dec 2022	Mar 2023	Jun 2023	Sept 2023	Dec 2023	Mar 2024	Jun 2024	Sept 2024
Promoter	74.88 %	74.88 %	74.88 %	74.88 %	74.88 %	74.88 %	74.98 %	74.98 %	74.98 %	74.98 %	74.98 %	74.98 %	74.98 %	74.98 %	74.98 %
FIIs	5.23 %	4.65 %	4.11 %	3.79 %	2.53 %	2.86 %	2.60 %	2.51 %	3.42 %	4.04 %	4.86 %	5.00 %	5.72 %	5.59 %	7.52 %
DIIs	11.29 %	10.50 %	11.25 %	11.80 %	12.82 %	11.95 %	12.95 %	13.70 %	13.60 %	13.52 %	13.09 %	13.03 %	12.63 %	12.64 %	10.65 %
Government	0.19 %	0.07 %	0.07 %	0.07 %	0.08 %	0.08 %	0.00 %	0.00 %	0.00 %	0.00 %	0.00 %	0.00 %	0.00 %	0.00 %	0.00 %
Public / Retail	8.40 %	9.90 %	9.69 %	9.46 %	9.69 %	10.24 %	9.48 %	8.81 %	8.00 %	7.47 %	7.07 %	6.99 %	6.66 %	6.80 %	6.85 %

Show % Change

Dividend History

Peer Comparison Compare Peers on Screener

Competitors	LTP	Market Cap (₹ Cr.)	P/E Ratio	Revenue (₹ Cr.)	YoY Revenue Growth %	Net Profit (₹ Cr.)	YoY Profit Growth %	RSI
Sun Pharmaceutical	1,774.25	4,25,929.94	38.00	49,887.17	12.06	9,648	27.35	40.28
Cipla	1,462.40	1,18,825.56	25.74	26,520.66	14.17	4,155	12.95	38.47
Mankind Pharma	2,534.95	1,02,885.42	48.65	10,615.63	19.57	1,942	28.89	46.80
Dr Reddys Laboratories	1,193.20	1,01,290.13	18.97	28,905.40	12.36	5,578	-9.47	32.64
Zydus Life Science	943.45	95,280.30	22.27	19,831.50	13.82	3,831	14.57	32.02
Lupin	2,037.15	92,929.19	35.38	20,141.50	19.94	1,936	73.52	37.01
Aurobindo Pharma	1,218.45	73,119.28	20.05	29,559.25	17.55	3,169	8.65	20.74
Alkem Laboratories	5,589.80	66,062.65	30.38	12,978.42	9.84	1,811	14.16	35.74
Glenmark Pharmaceuticals	1,464.05	42,112.35	-	12,653.09	6.58	-1,831	675.84	30.08
IPCA Laboratories	1,569.20	39,910.21	59.43	7,829.81	22.92	529	80.05	52.38